Home · Peptides · PE-22-28
THE PEPTIDE APP FIELD GUIDE · Healing SERIES FIELD SPECIMEN
Healing CATEGORY

PE-22-28

THE RAPID MOOD LIFTER

Spadin Analog; Shortened Spadin

PE-22-28 is a synthetic peptide derived from spadin that blocks TREK-1 potassium channels in the brain. This produces rapid antidepressant effects, often within days rather than the weeks typical of SSRIs. It promotes neurogenesis, protects neurons, and may help with stroke recovery. It's an exciting option for those seeking fast-acting mood support.

PE-22-28
PE-22-28
PE-22-28

PE-22-28 Evidence Snapshot

How these guides are reviewed
REGULATORY STATUS

Not FDA approved · research use only

DOSING GUIDANCE

Reviewed by our clinical team

LINKED EVIDENCE

1 research sources

CONTENT UPDATED

Aug 28, 2026

Dose and schedule recommendations shown below come from The Peptide App Clinical Team. Research links are provided so readers can inspect the supporting evidence directly. Review the sources.

Quick Answers About PE-22-28

◆

Is PE-22-28 FDA approved?

No. This profile records PE-22-28 as not FDA approved and for research use only.

MORE CONTEXT ›

Review the regulatory and source details on this page for the current context.

◆

What dose does The Peptide App Clinical Team recommend for PE-22-28?

Dose: 400 mcg intranasally each morning.

MORE CONTEXT ›

Schedule: daily. Cycle: 4 weeks on, 4 weeks off. This is clinical-team guidance for reference and does not replace individualized instructions from a licensed clinician.

◆

What research supports this PE-22-28 guide?

This guide links to 1 curated or current research sources.

MORE CONTEXT ›

Open the research section to inspect the source titles, publication details, study types, and available abstracts directly.

Studied Effects & Mechanisms

TREK-1 Blockade

Blocks potassium channels to stabilize neuronal membrane

Rapid Neurogenesis

Induces new brain cell growth within days

BDNF Upregulation

Increases brain-derived neurotrophic factor

Serotonin/Dopamine

Modulates monoamine neurotransmitter pathways

Those seeking rapid mood improvement
People who haven't responded to traditional antidepressants
Stroke recovery patients
Those interested in neurogenesis
Anyone wanting faster-acting mood support

PE-22-28 Research

Live research temporarily unavailable

The live research feed did not return papers for this page. The curated references below remain available for crawlable source context.